tion in DP16.1/p53ts cells was strongest at 8 hr (2.6-fold and 9.3-fold, respectively). com/cgi/content/full/112/6/779/DC1). The predicted protein contains a cysteine-rich RING motif defined by RNA samples from various cell lines were examined by Northern blotting to investigate the relationship between the consensus sequence CXXCX(9,39)CX(1,3)HX(2,3)C/ HXXCX(4,48)CXXC with eight cysteines and histidines p53 and Pirh2 expression. Pirh2 mRNA was induced in response to ␥-irradiation in wild-type MEFs (2.4-fold) that coordinate two zinc ions (Borden, 2000) . We have named this protein Pirh2 (for p53-induced protein with but not in p53 Ϫ/Ϫ MEFs ( Figure 1C ). We also observed induction of Pirh2 mRNA in response to cisplatin treata RING-H2 domain).
Northern blot analysis of RNA from various adult ment in the wild-type p53-expressing, murine pro B cell line, BaF3 (2.1-fold), but not in BaF3/DD cells, an isomouse tissues identified two Pirh2 mRNA transcripts with approximate lengths of 1.7 kb and 1.6 kb (Figure genic derivative expressing the C-terminal fragment of p53 ( Figure 1D ). This fragment has been shown to act 1A). Pirh2 mRNA expression was highest in the liver; relatively high levels were expressed in testis and heart, as a potent trans-dominant repressor of wild-type p53 through its ability to prevent the formation of functional and lower levels were expressed in muscle and spleen.
To confirm that Pirh2 is a p53-regulated gene, we p53 tetramers (Shaulian et al., 1992 ). In addition, we saw an increase in Pirh2 expression in cisplatin-treated studied the kinetics of Pirh2 induction in DP16.1/p53ts human BJT fibroblasts (2.5-fold) but not in the isogenic ing site at 19 out of 20 base pairs and contained an 8 bp spacer between the two half-sites. Electrophoretic derivative, BJT/DD, expressing the dominant-negative C-terminal fragment of p53 ( Figure 1E ). We also obmobility shift experiments indicated that p53 bound the Pirh2 element but not an unrelated control sequence served induction of Pirh2 mRNA in response to ␥-irradiation and UV-irradiation in mouse ES cells (data not ( Figure 2B ). We also tested the binding of p53 to the Pirh2 intron 3 site using chromatin immunoprecipitation shown). We did not detect any increase in the level of Pirh2 mRNA after ␥-irradiation in two wild-type p53 (ChIP). DP16.1/p53ts cells were grown at 32ЊC for 8 hr and subjected to ChIP analysis by immunoprecipitation expressing cell lines that we tested (MCF-7 and OCI/ AML-4) (data not shown). Moreover, we did not detect with control IgG or p53-specific polyclonal antibody (FL-393), followed by PCR analysis of the of the Pirh2 intron any increase in the level of Pirh2 in UV-irradiated MEFs or in UV-or ␥-irradiated BJT cells. Hence, the induction 3 region surrounding the p53 response element. Amplification of the Pirh2 promoter (Pirh2-Pr) and of a region of Pirh2 mRNA by p53 appears to be dependent on cell type and the DNA damaging agent used to activate p53. Figure 2C show that Pirh2 intron 3 was bound by p53 in vivo. covering the first four exons of Pirh2, including 8.6 kbp upstream of the first exon, revealed the presence of a To determine whether p53 activates transcription of a minimal promoter containing the p53 binding sequence putative p53 binding site within the third intron of Pirh2 (Figure 2A ). This site matched the consensus p53 bindpresent in intron 3 of Pirh2, a double-stranded oligonu-cleotide containing one copy of this element was in-GST-Pirh2 but not to GST alone ( Figure 3E ). Finally, we wished to determine if endogenous p53 and Pirh2 could serted into the luciferase reporter vector pGL3E1bTATA (designated Pirh2-Luc). Human Saos2 osteosarcoma interact under more physiological conditions in the absence of ectopic overexpression. An IP/Western blotting cells, which harbor a homozygous deletion of the p53 locus and do not produce p53 protein, were transfected experiment was performed using extracts prepared from human BJT fibroblasts. We observed that p53 coimmuwith Pirh2-Luc along with plasmids expressing either wild-type p53 or mutant p53 (p53 V143A). Wild-type p53 noprecipitated with Pirh2. In the reciprocal experiment using PAb1801 antibodies to immunoprecipitate p53, enhanced luciferase expression from Pirh2-Luc moderately, 3.7-fold. p53 V143A had no activity in these assays we observed that Pirh2 coimmunoprecipitated with p53 ( Figure 3F ). We conclude that p53 and Pirh2 physically ( Figure 2D ). In comparison, we found that luciferase expression from reporter plasmids containing the p53 interact in vivo. binding site from p21 WAF1 or from Mdm2 were stimulated 57-fold and 11-fold, respectively, by p53 (data not
Residues 120 Pirh2 Expression Reduces the Amount of Endogenous p53 Protein Binding between these molecules appeared not to be dependent on the RING-H2 domain of Pirh2. Next, Saos2
We tested the ability of Pirh2 to regulate the level of endogenous wild-type p53 protein in MCF-7 cells. Trancells were cotransfected with plasmids expressing Histagged Pirh2 and p53, and the extracts were immunosient overexpression of Pirh2 resulted in a reduction in the level of p53 ( Figure 5A ). In addition, we tested precipitated with a monoclonal antibody against His. p53 protein was detected in the anti-His immunoprecipiwhether endogenous Pirh2 is critical in regulating the level of p53 protein in BJT cells. An antisense oligonucletate confirming the in vivo interaction between p53 and Pirh2 ( Figure 3D ). Next, we performed an in vitro GST otide directed against Pirh2 effectively inhibited Pirh2 expression in BJT cells while a control-scrambled oligopull-down assay. Cell extracts were prepared from DP16.1 cells ectopically expressing mouse p53 and from nucleotide had no effect ( Figure 5B ). Importantly the decrease in Pirh2 was accompanied by an increase in Saos2 cells ectopically expressing human p53. p53 protein present in these extracts bound to immobilized the level of endogenous p53 protein ( Figure 5B ). Next, we generated a series of MCF-7 clones that stably excells. Cell extracts were subjected to immunoblotting with antibodies to Pirh2, Mdm2, or HA. Mdm2 and Pirh2 press hPirh2, Mdm2, or various hPirh2 mutants: ⌬RING (containing an internal deletion of the RING-H2 domain were expressed in the transfected cells ( Figure 6A ) and caused a large increase in protein ubiquitination that that removes residues 145 to 186), and C164A and H169A (in which the metal coordinating residues Cys164 was not seen in the absence of co-expressed HA-tagged ubiquitin ( Figure 6A , compare lanes 7 and 8 with lanes and His169 within the RING-H2 domain are replaced with Ala). The immunoblot shown in Figure 5C indicates 3 and 4). To determine if Pirh2 can promote ubiquitination of lower levels of endogenous p53 protein in clones expressing Pirh2 or Mdm2 in comparison with clones exp53 in vivo, p53 and HA-tagged ubiquitin were coexpressed in Saos2 cells together with Pirh2 or Mdm2. pressing Pirh2 RING mutants or with clones containing the empty vector. p53 mRNA levels were not affected Ectopically expressed p53 appeared as a doublet in these experiments; the smaller species may be the result by ectopic expression of Pirh2 (data not shown) indicating that p53 protein is the target of Pirh2. Together, of degradation or internal initiation. Importantly the overall level of p53 was lower when p53 was co-expressed these data indicate that Pirh2, like Mdm2, can regulate the steady-state level of p53 protein.
with Pirh2 or Mdm2 ( Figure 6A , lanes 2, 6, 9, and 10; Figure 6B , lanes 3-5) consistent with our previous results. We observed a massive increase in the amount Pirh2 Has Ubiquitin-Protein Ligase Activity To determine if Pirh2, like Mdm2, can mediate protein of protein ubiquitination when p53 was co-expressed with Mdm2 or with Pirh2 ( Figure 6A, lanes 9 and 10) . ubiquitination in vivo, vectors expressing Pirh2, Mdm2, and HA-tagged ubiquitin were transfected into Saos2
This level of ubiquitination was not seen with p53 alone 
S-labeled p53 was evaluated by SDS-PAGE and autoradiography and ubiquitination of purified GST-p53 was dation. evaluated by Western blotting. Higher molecular weight species indicative of addition of ubiquitin moieties on
Pirh2 Interferes with the Growth Inhibitory p53 were seen only in the presence of added E1 and Activity of p53 E2 (Figures 6G and 6H) .
Next, we investigated the effect of Pirh2 on p53-dependent growth suppression. We used a cotransfection assay in which the pCMV-CD20 expression vector enPirh2 Interferes with the Transcriptional Activity of p53 Protein coding the B cell surface marker CD20 was cotransfected with or without p53 into p53-negative H1299 cells. To investigate the functional consequences of Pirh2 interaction with p53, we tested the effect of Pirh2 expresThe number of CD20-positve cells was determined by flow cytometry 48 hr after transfection and a decrease sion on p53-mediated transcriptional activation. Saos2 cells were cotransfected with a luciferase reporter conin the number of CD20-positive cells provided a measure of p53-mediated cell death. Expression of p53 alone struct (p21-Luc) containing the p53 binding site from the p21 WAF1 promoter and p53, alone or in combination resulted in a reduction in cell viability and this was largely prevented by co-expressed Pirh2 ( Figure 7C ). To deterwith Pirh2 or Mdm2. As shown in Figure 7A control. inhibition could potentiate the ability of endogenous p53 to arrest BJT fibroblasts in the G1 phase of the cell cycle. Discussion BJT cells were exposed to control or Pirh2 antisense oligonucleotide and subjected to cell cycle analysis by
We propose that Pirh2 functions as a negative regulator of p53 and that it participates in an autoregulatory feedpropidium iodide staining and flow cytometry. Cells exposed to the control antisense oligonucleotide exhibited back loop with p53. In contrast with other p53 responsive genes, forced overexpression of Pirh2 in various a normal cell cycle profile ( Figure 7D ) and unchanged levels of Pirh2 and p53 protein ( Figure 5B ). In contrast, recipient cells did not result in cell cycle arrest or in the induction of apoptosis. This study raises the possibility BJT cells exposed to the Pirh2 antisense oligonucleotide (H) GST-Pirh2 was evaluated for its capacity to ubiquitinate purified His-p53. After the in vitro ubiquitination reaction, the samples were analyzed by SDS-PAGE and immunoblotting with a His antibody to reveal ubiquitinated products (top image) or with an antibody directed to p53 (Ab-7) to reveal ubiquitinated p53 species. that Pirh2 overexpression in cancer cells may provide these different forms of p53 are negatively regulated through distinct mechanisms. yet another mechanism to inactivate wild-type p53.
Our studies indicate that the RING-H2 domain of Pirh2 Pirh2 binds to the central core domain of p53 (residues 82-292) and Mdm2 binds to the N-terminal 52 amino is necessary for degradation of p53 and to impair the growth suppressing activity of p53. In contrast, the acid residues of the p53 protein ( acetic acid-insoluble radioactivity were immunoprecipitated with polyclonal antibodies to p53 (FL-393) and analyzed by gel electrophoresis and autoradiography. Cell Viability Assay H1299 cells were transfected using the calcium phosphate method with 3 g CMV-CD20 in the presence or absence of pcDNA3-p53
Chromatin Immunoprecipitation (5 g) and pcDNA3-hPirh2 or its variants (10 g). 
